Related Experiment Video
Updated: Jul 30, 2026
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
Published on: October 3, 2012
α-Arbutin Protects Against Parkinson's Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo
Yaqi Ding1, Deqin Kong2, Tong Zhou1
1Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), 30 South Puzhu Road, Nanjing, 211816, People's Republic of China.
Neuromolecular Medicine
|August 12, 2019
Summary
α-Arbutin (Arb) shows neuroprotective effects against Parkinson's disease (PD) models. This natural compound rescues mitochondrial dysfunction and apoptosis, offering potential as a novel PD therapeutic agent.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Parkinson's disease (PD) is a common neurodegenerative disorder marked by dopaminergic neuron loss.
- Current PD treatments are limited, and its pathogenesis remains unclear.
- Mitochondrial dysfunction is implicated in dopaminergic neuronal death in PD.
Purpose of the Study:
- To investigate the neuroprotective potential of α-Arbutin (Arb), a natural polyphenol, against PD.
- To elucidate the mechanisms underlying Arb's neuroprotective effects.
- To evaluate Arb's efficacy in both in vitro and in vivo PD models.
Main Methods:
- Utilized rotenone (Rot)-induced mitochondrial dysfunction and apoptosis in human neuroblastoma SH-SY5Y cells.
- Assessed oxidative stress, mitochondrial membrane potential, and ATP production.
- Investigated the involvement of AMP-activated protein kinase and autophagy pathways.
- Employed a drosophila PD model with parkin deficiency.
Main Results:
- α-Arbutin (Arb) significantly protected against rotenone-induced mitochondrial dysfunction and apoptosis in SH-SY5Y cells.
- Arb ameliorated oxidative stress, stabilized mitochondrial membrane potential, and enhanced ATP production.
- AMP-activated protein kinase and autophagy pathways were found to be involved in Arb's neuroprotection.
- Arb rescued motor function deficits and mitochondrial abnormalities in a drosophila PD model.
Conclusions:
- α-Arbutin (Arb) demonstrates significant neuroprotective effects in both in vitro and in vivo Parkinson's disease models.
- Arb's therapeutic potential stems from its ability to counteract mitochondrial dysfunction and oxidative stress.
- Arb shows promise as a novel therapeutic agent for Parkinson's disease treatment.
Related Concept Videos
01:37Mitochondria
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...